Abeona therapeutics announces updated eb-101 phase 1/2a clinical results in recessive dystrophic epidermolysis bullosa at the society for pediatric dermatology 46th annual meeting

New york and cleveland, july 07, 2021 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced updated phase 1/2a clinical trial results up to six years following treatment with abeona's investigational eb-101 for recessive dystrophic epidermolysis bullosa (rdeb). the data showed that investigator assessment of wound healing of 50% or greater from baseline was present in 69% of treated wounds (n=18/26) at 3 years, 93% (n=14/15) at 4 years, 80% (n=12/15) at 5 years, and 80% (n=4/5) at 6 years. the results were reported in a poster, titled “long-term healing, pain reduction, and patient-reported outcomes in recessive dystrophic epidermolysis bullosa following eb-101 treatment of large, chronic wounds,” at the society for pediatric dermatology (spd) 46th annual meeting.
ABEO Ratings Summary
ABEO Quant Ranking